A Phase Ib Open Label Positron Emission Tomography Study to Assess Changes in Intestinal [11C]AZ14132516 Uptake Following Administration of Multiple Doses of AZD7798 to Patients With Crohn's Disease.
Latest Information Update: 20 Feb 2025
At a glance
- Drugs AZD 7798 (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 12 Feb 2025 Planned End Date changed from 31 Mar 2026 to 14 Aug 2026.
- 12 Feb 2025 Planned primary completion date changed from 31 Mar 2026 to 14 Aug 2026.
- 20 Dec 2024 Planned number of patients changed from 24 to 12.